ELI LILLY AND COMPANY Available-for-sale Securities, Gross Realized Gains
ELI LILLY AND COMPANY (LLY) reported Available-for-sale Securities, Gross Realized Gains of $176.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-20.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGains · last filed 2018-11-06
- ELI LILLY AND COMPANY available-for-sale securities, gross realized gains for the quarter ending 2017-12-31 was $93.10M, a 633.07% increase year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized gains for the quarter ending 2017-09-30 was $9.00M, a 29.69% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized gains for the quarter ending 2017-06-30 was $22.20M, a 552.94% increase year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized gains for the quarter ending 2017-03-31 was $51.70M, a 2772.22% increase year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized gains for fiscal 2017 was $176.00M, a 473.29% increase from fiscal 2016.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized gains for fiscal 2016 was $30.70M, a 87.97% decline from fiscal 2015.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized gains for fiscal 2015 was $255.10M, a 27.84% decline from fiscal 2014.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized gains for fiscal 2014 was $353.50M, a 614.14% increase from fiscal 2013.
| Period end | Available-for-sale Securities, Gross Realized Gains 3 month | Available-for-sale Securities, Gross Realized Gains 6 month | Available-for-sale Securities, Gross Realized Gains 9 month | Available-for-sale Securities, Gross Realized Gains 12 month |
|---|---|---|---|---|
| 2017-12-31 | $93.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $102.10M derived: sum of 2 quarters · filed 2018-11-06 | $124.30M derived: sum of 3 quarters · filed 2018-11-06 | $176.00M 10-K · filed 2018-02-20 |
| 2017-09-30 | $9.00M 10-Q · filed 2018-11-06 | $31.20M derived: sum of 2 quarters · filed 2018-11-06 | $82.90M 10-Q · filed 2018-11-06 | $95.60M derived: sum of 4 quarters · filed 2018-11-06 |
| 2017-06-30 | $22.20M 10-Q · filed 2018-07-25 | $73.90M 10-Q · filed 2018-07-25 | $86.60M derived: sum of 3 quarters · filed 2018-07-25 | $99.40M derived: sum of 4 quarters · filed 2018-07-25 |
| 2017-03-31 | $51.70M 10-Q · filed 2018-04-27 | $64.40M derived: sum of 2 quarters · filed 2018-04-27 | $77.20M derived: sum of 3 quarters · filed 2018-04-27 | $80.60M derived: sum of 4 quarters · filed 2018-04-27 |
| 2016-12-31 | $12.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $25.50M derived: sum of 2 quarters · filed 2018-02-20 | $28.90M derived: sum of 3 quarters · filed 2018-02-20 | $30.70M 10-K · filed 2018-02-20 |
| 2016-09-30 | $12.80M 10-Q · filed 2017-10-27 | $16.20M derived: sum of 2 quarters · filed 2017-10-27 | $18.00M 10-Q · filed 2017-10-27 | $19.80M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-06-30 | $3.40M 10-Q · filed 2017-07-28 | $5.20M 10-Q · filed 2017-07-28 | $7.00M derived: sum of 3 quarters · filed 2018-02-20 | $158.00M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-03-31 | $1.80M 10-Q · filed 2017-05-01 | $3.60M derived: sum of 2 quarters · filed 2018-02-20 | $154.60M derived: sum of 3 quarters · filed 2018-02-20 | $202.40M derived: sum of 4 quarters · filed 2018-02-20 |
| 2015-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $152.80M derived: sum of 2 quarters · filed 2018-02-20 | $200.60M derived: sum of 3 quarters · filed 2018-02-20 | $255.10M 10-K · filed 2018-02-20 |
| 2015-09-30 | $151.00M 10-Q · filed 2016-10-28 | $198.80M derived: sum of 2 quarters · filed 2016-10-28 | $253.30M 10-Q · filed 2016-10-28 | $349.50M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $47.80M 10-Q · filed 2016-07-28 | $102.30M 10-Q · filed 2016-07-28 | $198.50M derived: sum of 3 quarters · filed 2017-02-21 | $291.20M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $54.50M 10-Q · filed 2016-04-29 | $150.70M derived: sum of 2 quarters · filed 2017-02-21 | $243.40M derived: sum of 3 quarters · filed 2017-02-21 | $328.20M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $96.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $188.90M derived: sum of 2 quarters · filed 2017-02-21 | $273.70M derived: sum of 3 quarters · filed 2017-02-21 | $353.50M 10-K · filed 2017-02-21 |
| 2014-09-30 | $92.70M 10-Q · filed 2015-10-30 | $177.50M derived: sum of 2 quarters · filed 2015-10-30 | $257.30M 10-Q · filed 2015-10-30 | $265.00M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | $84.80M 10-Q · filed 2015-07-30 | $164.60M 10-Q · filed 2015-07-30 | $172.30M derived: sum of 3 quarters · filed 2016-02-19 | $175.90M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | $79.80M 10-Q · filed 2015-04-30 | $87.50M derived: sum of 2 quarters · filed 2016-02-19 | $91.10M derived: sum of 3 quarters · filed 2016-02-19 | $119.30M derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $11.30M derived: sum of 2 quarters · filed 2016-02-19 | $39.50M derived: sum of 3 quarters · filed 2016-02-19 | $49.50M 10-K · filed 2016-02-19 |
| 2013-09-30 | $3.60M 10-Q · filed 2014-10-29 | $31.80M derived: sum of 2 quarters · filed 2014-10-29 | $41.80M 10-Q · filed 2014-10-29 | $54.10M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $28.20M 10-Q · filed 2014-07-28 | $38.20M 10-Q · filed 2014-07-28 | $50.50M derived: sum of 3 quarters · filed 2015-02-19 | $93.60M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $10.00M 10-Q · filed 2014-04-28 | $22.30M derived: sum of 2 quarters · filed 2015-02-19 | $65.40M derived: sum of 3 quarters · filed 2015-02-19 | $78.60M derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $55.40M derived: sum of 2 quarters · filed 2015-02-19 | $68.60M derived: sum of 3 quarters · filed 2015-02-19 | $82.30M 10-K · filed 2015-02-19 |
| 2012-09-30 | $43.10M 10-Q · filed 2013-10-30 | $56.30M derived: sum of 2 quarters · filed 2013-10-30 | $70.00M 10-Q · filed 2013-10-30 | $96.40M derived: sum of 4 quarters · filed 2014-02-19 |
| 2012-06-30 | $13.20M 10-Q · filed 2013-07-26 | $26.90M 10-Q · filed 2013-07-26 | $53.30M derived: sum of 3 quarters · filed 2014-02-19 | $78.90M derived: sum of 4 quarters · filed 2014-02-19 |
| 2012-03-31 | $13.70M 10-Q · filed 2013-04-26 | $40.10M derived: sum of 2 quarters · filed 2014-02-19 | $65.70M derived: sum of 3 quarters · filed 2014-02-19 | $114.30M derived: sum of 4 quarters · filed 2014-02-19 |
| 2011-12-31 | $26.40M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $52.00M derived: sum of 2 quarters · filed 2014-02-19 | $100.60M derived: sum of 3 quarters · filed 2014-02-19 | $140.00M 10-K · filed 2014-02-19 |
| 2011-09-30 | $25.60M 10-Q · filed 2012-10-26 | $74.20M derived: sum of 2 quarters · filed 2012-10-26 | $113.60M 10-Q · filed 2012-10-26 | $141.90M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $48.60M 10-Q · filed 2012-07-27 | $88.00M 10-Q · filed 2012-07-27 | $116.30M derived: sum of 3 quarters · filed 2013-02-21 | $124.10M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $39.40M 10-Q · filed 2012-04-30 | $67.70M derived: sum of 2 quarters · filed 2013-02-21 | $75.50M derived: sum of 3 quarters · filed 2013-02-21 | $86.90M derived: sum of 4 quarters · filed 2013-02-21 |
| 2010-12-31 | $28.30M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $36.10M derived: sum of 2 quarters · filed 2013-02-21 | $47.50M derived: sum of 3 quarters · filed 2013-02-21 | $110.70M 10-K · filed 2013-02-21 |
| 2010-09-30 | $7.80M 10-Q · filed 2011-10-28 | $19.20M derived: sum of 2 quarters · filed 2011-10-28 | $82.40M 10-Q · filed 2011-10-28 | $94.50M derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-06-30 | $11.40M 10-Q · filed 2011-07-29 | $74.60M 10-Q · filed 2011-07-29 | $86.70M derived: sum of 3 quarters · filed 2012-02-24 | $126.20M derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-03-31 | $63.20M 10-Q · filed 2011-04-29 | $75.30M derived: sum of 2 quarters · filed 2012-02-24 | $114.80M derived: sum of 3 quarters · filed 2012-02-24 | $127.20M derived: sum of 4 quarters · filed 2012-02-24 |
| 2009-12-31 | $12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $51.60M derived: sum of 2 quarters · filed 2012-02-24 | $64.00M derived: sum of 3 quarters · filed 2012-02-24 | $68.90M 10-K · filed 2012-02-24 |
| 2009-09-30 | $39.50M 10-Q · filed 2010-10-29 | $51.90M derived: sum of 2 quarters · filed 2010-10-29 | $56.80M 10-Q · filed 2010-10-29 | |
| 2009-06-30 | $12.40M 10-Q/A · filed 2010-08-02 | $17.30M 10-Q/A · filed 2010-08-02 | ||
| 2008-12-31 | $45.70M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |